1. Peptide immunotherapy;Larche;Immunol. Allergy Clin. North Am.,2006
2. Evaluation of near-fatal reactions to allergen immunotherapy injections;Amin;J. Allergy Clin. Immunol.,2006
3. A. Committee, Advisory Committee Clinical Efficacy Briefing Document, Genentech, Inc.: omalizumab for asthma, Biologics Marketing Application STN 103976/0 DHHS, PHS, FDA (2003) 1–118.
4. The pharmacological basis of anti-IgE therapy;Chang;Nat. Biotechnol.,2000
5. M. Hitti, L. Chang, Xolair gets ‘Black Box’ warning, WebMD Medical News (2007) July 3.